CARLSBAD, Calif.--(BUSINESS WIRE)--Invitrogen Corporation (Nasdaq:IVGN), a provider of essential life science technologies for disease research and drug discovery, today announced it has launched a program whereby GIBCO® cell culture media products and platforms offered by PD-DirectTM Bioprocess Services are evaluated in concert with third party technologies. Invitrogen’s program expands the range of cell culture production options available to customers. Under this initiative, third party technologies are pre-screened against Invitrogen’s cell culture products. Services engagements with technology owners can generate further optimization of cell culture products for client-specific applications.
